Indole-pyrimidine hybrids with anticancer therapeutic potential
Zhang Bin1,2,3, Zhao Bing1, Li Xinchun1
1Affiliated Zhumadian Central Hospital, Huanghuai University, Zhumadian, China.
Abstract:
Indole derivatives constitute a structurally heterogeneous and clinically promising class of anticancer agents. Notably, their biological activity stems from targeting multiple hallmarks of cancer, including dysregulated proliferation, apoptotic evasion, angiogenesis, and epigenetic perturbations, the key processes that drive malignant progression. The indole framework facilitates ready structural modification, enabling specific binding to cancer-selective molecular targets. By comparison, pyrimidine derivatives owe their capacity to act as "molecular mimics" or enzyme inhibitors to their structural analogy to endogenous pyrimidines, which allows them to capitalize on cancer-specific vulnerabilities. Thus, the rational hybridization of indole and pyrimidine scaffolds represents a promising strategy for the development of novel and potent anticancer therapeutics. The present work aims to summarize the current landscape of indole-pyrimidine hybrids with anticancer potential, covering articles published from 2021 to date. The structure-activity relationships and the mechanisms of action are also discussed for further rational design of novel anticancer drug candidates.
Insights
Indole-pyrimidine hybrids show promise as anticancer agents by targeting multiple cancer hallmarks. This review summarizes recent advances in these compounds, focusing on structure-activity relationships and mechanisms of action for drug development.
Area of Science:
- Medicinal Chemistry
- Drug Discovery
- Oncology
Background:
- Indole derivatives are versatile anticancer agents targeting cancer hallmarks like proliferation and apoptosis.
- Pyrimidine derivatives act as molecular mimics or enzyme inhibitors, exploiting cancer-specific vulnerabilities.
- Hybridizing indole and pyrimidine scaffolds offers a promising strategy for novel anticancer therapeutics.
Purpose of the Study:
- To review the current landscape of indole-pyrimidine hybrids with anticancer potential.
- To summarize structure-activity relationships and mechanisms of action for these hybrids.
- To guide the rational design of new anticancer drug candidates.
Main Methods:
- Literature search for indole-pyrimidine hybrids with anticancer activity published from 2021 to date.
- Analysis of structure-activity relationships (SAR) of identified compounds.
- Discussion of mechanisms of action for promising drug candidates.
Main Results:
- Identified a growing body of research on indole-pyrimidine hybrids demonstrating significant anticancer potential.
- Detailed SAR studies reveal key structural features contributing to efficacy.
- Mechanisms of action involve targeting multiple cancer pathways.
Conclusions:
- Indole-pyrimidine hybrids represent a potent class of anticancer agents with diverse mechanisms.
- Further research into SAR and mechanisms will facilitate the development of novel therapeutics.
- This hybrid scaffold holds significant promise for future cancer drug discovery.
More Related Videos
06:34Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS
Published on: June 20, 2014
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Tumor Immunotherapy
